Novartis AG Common Stock (NY:NVS)

141.00 UNCHANGED

Delayed Quote Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

59 60 Next >

2 Surefire Dividend Stocks to Buy for the Long Haul ↗

October 04, 2025

Both have crushed the market in 2025.

Via The Motley Fool

Decoding Life's Blueprint: New Tech Maps RNA-Protein Interactions, Unlocking Disease Cures

October 02, 2025

A monumental leap in biomedical research has been announced with the development of a breakthrough technology capable of mapping the entire intricate network of RNA-protein interactions within human...

Via MarketMinute

Topics Artificial Intelligence Derivatives

Amgen Surges on Repatha Expansion, Manufacturing Boost, and Strong Earnings

October 02, 2025

Thousand Oaks, CA – October 2, 2025 – Amgen (NASDAQ: AMGN) has witnessed a robust surge in its share price, climbing approximately 6% in recent trading sessions, culminating on October 2, 2025, to...

Via MarketMinute

Topics Economy Intellectual Property Stocks

Monte Rosa Therapeutics Stock Scores Biggest Gain In Nearly A Year On $5.7B Novartis Deal For Immune-Mediated Diseases ↗

September 15, 2025

Via Stocktwits

Google DeepMind Chief Eyes Radical AI-Powered Shift In Drug Discovery Speed — Eli Lilly, Novartis Are Already Onboard ↗

September 12, 2025

Via Stocktwits

Generative AI Unleashes a New Era in Genome Editing, Outperforming Nature in Protein Design

October 02, 2025

London, UK – October 2, 2025 – In a monumental stride for biotechnology and medicine, generative artificial intelligence (AI) has achieved a scientific breakthrough, demonstrating an unprecedented...

Via TokenRing AI

Topics Artificial Intelligence

AI Revolutionizes Pharma: Market Soars Towards $65 Billion by 2033, Promising a New Era of Medicine

October 02, 2025

The pharmaceutical industry is on the cusp of a profound transformation, driven by the accelerating integration of Artificial Intelligence (AI). Projections indicate that the global AI in...

Via TokenRing AI

Topics Artificial Intelligence Economy

Cullen Trims KVUE Stake With $149.5M Share Sale ↗

October 01, 2025

Via The Motley Fool

Topics Regulatory Compliance

Healthcare Sector Navigates Turbulent Waters as Drug Pricing Agreements Reshape Market Landscape

September 30, 2025

September 30, 2025 – The healthcare sector today finds itself at a pivotal juncture, experiencing a complex mix of optimism and apprehension. While a landmark drug-pricing agreement between...

Via MarketMinute

Topics Artificial Intelligence Economy Government

Cullen Sells 1.4 Million Dow Shares Worth $39.7 Million Amid Steep Stock Decline ↗

September 30, 2025

Via The Motley Fool

Topics Stocks

Pharma's Direct-To-Patient Wave Hits Novartis Next ↗

September 29, 2025

The Pharmaceutical Research and Manufacturers of America (PhRMA) outlined initiatives to bolster U.S. manufacturing, ease patient costs, and improve access to medicine.

Via Benzinga

Digital Pharma Advances 2026: AI and Patient-Centric Strategies Transform Pharma Marketing

September 29, 2025

Via PRLog

Topics Artificial Intelligence

AstraZeneca's Strategic Listing Harmonization: A Unified Global Platform for Growth

September 29, 2025

AstraZeneca (LSE: AZN, NASDAQ: AZN) has announced a significant strategic move to harmonize its stock market listings across the London Stock Exchange (LSE), Nasdaq Stockholm (STO), and the New York...

Via MarketMinute

Topics Economy

Novartis AG-Sponsored ADR (NYSE:NVS): A Strong Dividend Stock with High Profitability and Sound Financial Health ↗

September 29, 2025

Novartis (NVS) offers a strong 3.58% dividend yield with a history of steady payments, supported by high profitability and sound financial health for sustainable income.

Via Chartmill

Major Insider Sale Casts Shadow on LENZ Therapeutics' Valuation

September 27, 2025

San Diego, CA – September 27, 2025 – LENZ Therapeutics (NASDAQ: LENZ) is facing heightened scrutiny this week following a significant insider share sale by a major shareholder, Versant Venture Capital...

Via MarketMinute

Topics Artificial Intelligence

Pharma Tariffs Back In Spotlight On New Trump Threat ↗

September 26, 2025

President Donald Trump threatened 100% tariffs on some drug imports.

Via Investor's Business Daily

Topics ETFs Government World Trade

Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet ↗

September 26, 2025

Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de

Via Benzinga

Topics Government World Trade

Trump's New Tariff Barrage Targets Drugs, Trucks, Cabinets: President Says Move Will Protect Manufacturers From 'Unfair Outside Competition' ↗

September 25, 2025

President Donald Trump announced a barrage of new tariffs on Thursday, aimed at pharmaceuticals, heavy trucks and home furnishings in particular, to shore up domestic industry in these sectors, and...

Via Benzinga

Topics Government World Trade

Eli Lilly Stock Is Trading Down Thursday: What's Behind The Move? ↗

September 25, 2025

Eli Lilly and Company (NYSE: LLY) shares are trading lower after the company ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it...

Via Benzinga

AI Takes Center Stage in Biodefense: DARPA's NODES Program Promises to Revolutionize Pandemic and Biowarfare Protection

September 25, 2025

In a groundbreaking leap for global health security, the Defense Advanced Research Projects Agency (DARPA) officially launched its Network of Optimal Dynamic Energy Signatures (NODES) program in July...

Via MarketMinute

Topics Artificial Intelligence

Eli Lilly Ends Bimagrumab Obesity Study Weeks After Launch ↗

September 25, 2025

On Wednesday, Eli Lilly & Co. (NYSE: LLY) ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it began.

Via Benzinga

Novartis, AbbVie Face Legal Defeat Over 340B Contract Pharmacies ↗

September 24, 2025

A judge upholds Maine's contract pharmacy law, rejecting drugmakers' claims that it conflicts with federal rules governing the 340B drug discount program.

Via Benzinga

Scholar Rock's Spinal Muscular Atrophy Drug Faces FDA Delay Over Catalent Indiana Inspection ↗

September 23, 2025

FDA cites Catalent Indiana issues in Scholar Rock's SMA drug review; European approval decision expected in 2026, with Germany as the launch market.

Via Benzinga

Roche Targets Top Spot In Weight Loss Drug Market ↗

September 22, 2025

Roche advances weight loss drug CT-388 to Phase III, boosts pipeline with major acquisitions.

Via Benzinga

Novartis Builds US Drug Reserves Against Potential Tariffs ↗

September 22, 2025

Novartis bolsters U.S. drug reserves and plans $23 billion in investments as CEO Vas Narasimhan addresses tariff risks and trade policy uncertainty.

Via Benzinga

Topics World Trade

Lilly's AI Gambit: TuneLab Poised to Reshape Biotech Drug Discovery Landscape

September 19, 2025

Eli Lilly and Company (NYSE: LLY) has unveiled its groundbreaking TuneLab Platform, an artificial intelligence (AI) and machine learning (ML) initiative designed to democratize advanced drug discovery...

Via MarketMinute

Topics Animal Testing Artificial Intelligence Intellectual Property

Lilly's Oncology Momentum Soars: Olomorasib Gains Breakthrough Status, Jaypirca Achieves Landmark Clinical Successes

September 19, 2025

Eli Lilly and Company (NYSE: LLY) is making significant waves in the oncology landscape with a series of major announcements concerning two of its innovative cancer therapies: Olomorasib and Jaypirca...

Via MarketMinute

Monte Rosa, Novartis Use AI-Powered Engine To Advance Immune Disease Treatments ↗

September 15, 2025

Monte Rosa's stock jumps as it partners with Novartis to develop degraders for immune diseases, with up to $5.7 billion in payments.

Via Benzinga

Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Compelling Case for Value Investors ↗

September 15, 2025

Discover Novartis (NVS), an undervalued pharma stock with strong fundamentals, high profitability, and a solid margin of safety for value investors.

Via Chartmill

This Applied Materials Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday ↗

September 12, 2025

Via Benzinga

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

59 60 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.